Could a common drug ease the burden of Long-COVID and ME/CFS?
NCT ID NCT06257420
First seen May 13, 2026 · Last updated May 21, 2026 · Updated 3 times
Summary
This study looks at whether low-dose rapamycin can reduce symptoms and improve quality of life in people with ME/CFS or Long-COVID. Researchers will track 150 participants through questionnaires and blood tests to see how the drug affects fatigue and daily function. The goal is to understand if rapamycin helps control these chronic conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bateman Horne Center
Salt Lake City, Utah, 84102, United States
-
Center For Complex Diseases
Palo Alto, California, 94040, United States
-
Center For Complex Diseases
Seattle, Washington, 98109, United States
-
Sierra Internal Medicine
Incline Village, Nevada, 89451, United States
-
The Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.